摘要
溶栓是目前急性缺血性脑卒中的一种重要治疗方法,能有效降低脑卒中后致残。阿替普酶是唯一被FDA批准用于治疗急性缺血性脑卒中的药物,但是有很多局限性。近年来,为了提高溶栓治疗的安全性和有效性,对一些重组组织型纤溶酶原激活剂进行了临床应用可行性研究。对急性缺血性脑卒中溶栓治疗的发展过程和组织型纤溶酶原激活剂在中枢神经系统中的病理生理功能进行回顾,并对阿替普酶和其他几种主要的重组组织型纤溶酶原激活剂作一综述。
Thrombolysis for acute ischaemic stroke is a key interventxon that can reauce alsaolnty from stroke. Intravenous thrombolysis with alteplase is the only approved treatment for acute ischaemic stroke by U. S. Food and Drug Administration but has several limitations. Several feasibility studies on the clinical application of recombinant tissue plasminogen activator were carried out in order to improve the efficacy and safety of thrombolytic therapy in recent years. The developing process of thrombolysis with alteplase and other recombinant tissue plasminogen activators for acute ischaemic stroke as well as their pathological and physiological function in the central nervous system were reviewed.
出处
《中国临床神经科学》
2013年第3期348-352,共5页
Chinese Journal of Clinical Neurosciences
